Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.

Study Overview

• Status: Active, not recruiting
• Conditions: Neoplasms
• Intervention / Treatment: Drug: Letetresgene autoleucel (lete-cel, GSK3377794); Drug: Fludarabine; Drug: Cyclophosphamide

Detailed Description

New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumor-associated proteins that have been found in several tumor types. Clinical trials using adoptively transferred T cells directed against NY-ESO-1/LAGE-1a have shown objective responses. Letetresgene autoleucel (lete-cel, GSK3377794) is the first generation of NY-ESO-1 specific T-cell receptor engineered T cells. This is a master protocol investigating T-cell therapies. It will initially consist of a core protocol with two independent substudies investigating Letetresgene autoleucel in previously untreated (1L) Human Leukocyte Antigen (HLA)-A*02+ participants with NY-ESO-1+ advanced (metastatic or unresectable) synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS) (Substudy 1) and Letetresgene autoleucel as second line or higher (2L+) treatment in HLA-A*02+ participants with NY-ESO-1+ advanced (metastatic or unresectable) SS or MRCLS who have progressed following treatment with anthracycline based chemotherapy (Substudy 2).

• Study Type: Interventional
• Enrollment (Actual): 103
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 2M9
      • Princess Margaret Cancer Centre
  • Quebec
    • Montreal, Quebec, Canada, H1T 2M4
      • CIUSSS de L'Est-De-Lile-De-Montreal
• France
  • Lyon, France, 69373
    • Centre Léon Bérard
  • Pessac, France, 33604
    • CHU de Bordeaux GH Sud Hôpital Haut Lévêque
• Italy
  • Lombardy
    • Milan, Lombardy, Italy, 20133
      • Fondazione IRCCS Instituto Nazionale Dei Tumori
    • Rozzano (MI), Lombardy, Italy, 20089
      • Ircss Istituto Clinico Humanitas
• Netherlands
  • Amsterdam, Netherlands, 1066 CX
    • The Netherlands Cancer Institute
• Spain
  • Barcelona, Spain, 08025
    • Hospital Santa Creu Y Sant Pau
  • Hospitalet de Llobregat, Barcelona, Spain, 08907
    • Ico Duran y Reynals l'Hospitalet de Llobrega
  • Madrid, Spain, 28040
    • Hospital Universitario Fundacion Jimenez Diaz
  • Seville, Spain, 41013
    • Hospital Virgen del Rocío
• United Kingdom
  • London, United Kingdom, SW3 6JJ
    • Royal Marsden Hospital
  • London, United Kingdom, WC1E 6AG
    • University College Hospital-London
  • Manchester, United Kingdom, M20 4BX
    • Christie Hospital NHS Foundation Trust
• United States
  • California
    • Duarte, California, United States, 91010
      • City Of Hope National Medical Center
    • Stanford, California, United States, 94305
      • Stanford Hospital and Clinics
  • Colorado
    • Denver, Colorado, United States, 80218
      • Sarah Cannon Research Institute
  • Florida
    • Jacksonville, Florida, United States, 32224
      • Mayo Clinic Jacksonville
  • Illinois
    • Chicago, Illinois, United States, 60637
      • University of Chicago
  • Iowa
    • Iowa City, Iowa, United States, 52242-1009
      • University of Iowa College of Medicine
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital
    • Boston, Massachusetts, United States, 02114
      • Dana Farber Cancer Institute
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan Medical Center
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Minnesota Oncology Hematology
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic Rochester
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Washington University
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke University Medical Center
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Ohio State University-Columbus
  • Oregon
    • Portland, Oregon, United States, 97239
      • Oregon Health and Science University
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15232
      • University of Pittsburgh, Hillman Cancer Centre
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Sarah Cannon Research Institute
  • Texas
    • Dallas, Texas, United States, 75390-9063
      • University of Texas Southwestern Medical Center
    • Dallas, Texas, United States, 75390-8565
      • University of Texas Southwestern Medical Center
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • University of Utah
  • Virginia
    • Richmond, Virginia, United States, 23298
      • Virginia Commonwealth University
  • Washington
    • Seattle, Washington, United States, 98109-1024
      • Fred Hutchinson Cancer Research
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Froedtert Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant must be greater than or equal to 10 years of age on the day of signing informed consent.
• Participant scheduled to receive clinical drug product supply must also weigh ≥40 kg
• Participant must be positive for HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 alleles by a designated central laboratory
• Participant's tumor is positive for NY-ESO-1 expression by a designated central laboratory.
• Participant has a diagnosis of synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS)
• Performance status: dependent on age - Lansky > 60, Karnofsky > 60, Eastern Cooperative Oncology Group 0-1.
• Participant must have adequate organ function and blood cell counts, within 7 days prior to leukapheresis.
• At time of treatment, participant has measurable disease according to RECIST v1.1.
• Male or female. Contraception requirements will apply at the time of leukapheresis and treatment.
• Consultation for prior history per protocol specifications.

Exclusion Criteria:

• Central nervous system metastases.
• Any other prior malignancy that is not in complete remission.
• Clinically significant systemic illness (Serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction, that in the judgment of the Investigator would compromise the participant's ability to tolerate protocol therapy or significantly increase the risk of complications).
• Prior or active demyelinating disease.
• History of chronic or recurrent (within the last year prior to leukapheresis) severe autoimmune or immune mediated disease (e.g. Crohn's disease, systemic lupus) requiring steroids or other immunosuppressive treatments.
• Previous treatment with genetically engineered NY-ESO-1-specific T cells.
• Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody.
• Prior gene therapy using an integrating vector.
• Previous allogeneic hematopoietic stem cell transplant.
• Washout periods for prior radiotherapy and systemic chemotherapy must be followed.
• Participant had major surgery in less than or equal to 28 days of first dose of study intervention.
• Prior radiation exceeds protocol specified limits.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Substudy 1: lete-cel in previously untreated advanced (metastatic or unresectable) SS or MRCLS; Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.	Drug: Letetresgene autoleucel (lete-cel, GSK3377794); letetresgene autoleucel will be administered.; Drug: Fludarabine; Fludarabine will be used as the lymphodepleting chemotherapy; Drug: Cyclophosphamide; Cyclophosphamide will be used as the lymphodepleting chemotherapy.
Experimental: Substudy 2: lete-cel in advanced (metastatic or unresectable) SS or MRCLS post anthracycline chemo; Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.	Drug: Letetresgene autoleucel (lete-cel, GSK3377794); letetresgene autoleucel will be administered.; Drug: Fludarabine; Fludarabine will be used as the lymphodepleting chemotherapy; Drug: Cyclophosphamide; Cyclophosphamide will be used as the lymphodepleting chemotherapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Substudy 1: Overall response rate (ORR)	Overall response rate is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) relative to the total number of participants within the analysis population at any time per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. as determined by the local investigators.	Until disease progression (up to 5 years)
Substudy 2: Overall response rate (ORR) as assessed by central independent review	Overall response rate is defined as the percentage of participants with a confirmed CR or PR relative to the total number of participants within the analysis population at any time per RECIST v1.1. as assessed by central independent review.	Up to 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Substudy 1 and 2: Time to response (TTR)	Time to response is defined as time from date of T-cell administration to first documented evidence of confirmed (CR or PR) as assessed by local investigators per RECIST v1.1.	Until disease progression (up to 5 years)
Substudy 1 and 2: Duration of response (DOR)	Duration of response is defined as, in the subset of participants who show a confirmed CR or PR as assessed by local investigators, the time from first documented evidence of CR or PR until the first documented sign of disease progression or death.	Until disease progression (up to 5 years)
Substudy 1 and 2: Disease control rate (DCR)	Disease control rate is defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) with minimal 12 weeks duration relative to the total number of participants within the analysis population at the time of primary analysis as determined by Investigators per RECIST v1.1.	Until disease progression (up to 5 years)
Substudy 1 and 2: Progression free survival (PFS)	Progression free survival is defined as the time from the date of T-cell administration until first documented sign of disease progression per RECIST v1.1, or death.	Until disease progression (up to 5 years)
Substudy 1 and 2: Frequency of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI) according to severity	AEs, SAEs and AESIs will be collected. Severity of AEs and SAEs will be summarized using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.	Until disease progression (up to 5 years)
Substudy 1 and 2: Number of participants with replication competent lentivirus (RCL)	RCL exposure will be assessed by polymerase chain reaction (PCR) based assay.	Until disease progression (up to 5 years)
Substudy 1 and 2: Number of participants with insertional oncogenesis (IO)	Peripheral blood mononuclear cells (PBMC) samples will be collected for monitoring insertional oncogenesis by PCR for gene modified cells in the blood.	Until disease progression (up to 5 years)
Substudy 2: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis parameters	Blood and urine samples will be collected for assessment of hematology, clinical chemistry and urinalysis parameters.	Until disease progression (up to 5 years)
Substudy 1 and 2: Maximum transgene expansion (Cmax) of letetresgene autoleucel	Whole blood samples will be collected at indicated time points for evaluation of Cmax.	Until disease progression (up to 5 years)
Substudy 1 and 2: Time to Cmax (Tmax) of letetresgene autoleucel	Whole blood samples will be collected at indicated time points for evaluation of Tmax.	Until disease progression (up to 5 years)
Substudy 1 and 2: Area under the concentration/persistence time curve from zero to time t (AUC[0-t]) of letetresgene autoleucel	Whole blood samples will be collected at indicated time points for evaluation of AUC(0-t).	Until disease progression (up to 5 years)
Substudy 2: Overall response rate (ORR) as determined by the local investigators	Overall response rate is defined as the percentage of participants with a confirmed CR or PR relative to the total number of participants within the analysis population at any time per RECIST v1.1. as determined by the local investigators.	Up to 5 years
Substudy 2: Overall Survival (OS)	Overall Survival is defined as the interval of time between the date of T-cell infusion and the date of death.	Up to 5 years
Substudy 2: Number of participants with positive anti-drug antibodies (ADA) and titers of ADA against letetresgene autoleucel	Serum samples will be collected to analyze for the presence of ADAs using validated immunoassays.	Up to 36 months

Collaborators and Investigators

• Sponsor: USWM CT, LLC
• Investigators: Study Director: Michael Nathenson, MD, USWM CT, LLC

Study record dates

Study Major Dates

• Study Start (Actual): December 31, 2019
• Primary Completion (Actual): March 1, 2024
• Study Completion (Estimated): July 31, 2026

Study Registration Dates

• First Submitted: May 10, 2019
• First Submitted That Met QC Criteria: May 28, 2019
• First Posted (Actual): May 30, 2019

Study Record Updates

• Last Update Posted (Actual): April 17, 2026
• Last Update Submitted That Met QC Criteria: April 15, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Leukapheresis; Adoptive T-cell therapy; GSK3377794; Letetresgene autoleucel; Synovial sarcoma; Advanced metastatic disease; Advanced unresectable disease; Myxoid/round cell liposarcoma; Positive solid tumors; T-cell receptors; Lete-cel
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Sarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms, Connective Tissue; Neoplasms, Adipose Tissue; Liposarcoma; Neoplasms; Sarcoma, Synovial; Liposarcoma, Myxoid; Organic Chemicals; Hydrocarbons; Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Phosphoramides; Organophosphorus Compounds; Cyclophosphamide; fludarabine
• Other Study ID Numbers: 208467

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
• IPD Sharing Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
• IPD Sharing Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No